Sign up to save your podcasts
Or
Share Nephron Research: Myriad Genetics (MYGN) PRIME Care Study KOL Call w/ Dr. Charlie Nemeroff
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Nephron Research: Myriad Genetics (MYGN) PRIME Care Study KOL Call w/ Dr. Charlie Nemeroff
Myriad published the results of the PRIME Care Study on Tuesday afternoon in JAMA. In the 2K patient study, GeneSight was successful on both of the co-primary endpoints. Despite the rosy headlines, the devil is always in the details! Such was the case with the GUIDED Study published in 2019.
To help pick through the results, Nephron hosted a Q&A call with the leading KOL in the category of pharmacogenetics: Dr. Charlie Nemeroff. Topics of discussion included a review of the PRIME Care study, the pros and cons of the data, implications for clinical adoption of the test and payor coverage, and thoughts on the regulatory environment for pharmacogenetic testing. The primary company in focus wasMyriad Genetics (MYGN).
View all episodes
By Nephron Research LLCMyriad published the results of the PRIME Care Study on Tuesday afternoon in JAMA. In the 2K patient study, GeneSight was successful on both of the co-primary endpoints. Despite the rosy headlines, the devil is always in the details! Such was the case with the GUIDED Study published in 2019.
To help pick through the results, Nephron hosted a Q&A call with the leading KOL in the category of pharmacogenetics: Dr. Charlie Nemeroff. Topics of discussion included a review of the PRIME Care study, the pros and cons of the data, implications for clinical adoption of the test and payor coverage, and thoughts on the regulatory environment for pharmacogenetic testing. The primary company in focus wasMyriad Genetics (MYGN).